TechnoDerma Management Team（From left to right: Wenkui Fang, Ph.D., Zengquan Wang, Ph.D. and Guanqun Li, M.D./Ph.D.)
On Aug 9th, 2022, US Pacific Time, Technoderma Medicines (TDM), a drug discovery startup specialized in dermatology indications based at Jiaxing, China,announced that FDA approved the IND application of its novel experimental drug for the topical treatmen
Technoderma Medicines, Inc., a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing in its Phase 1b (MAD) clinical trial of topical TDM-105795 solution in patients with Androgenetic Alopecia (AGA).
Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun recruitment for its second Phase 1 clinical trial of topical TDM-105795 in patients with Androgenetic Alopecia (AGA).
TechnoDerma has recently announced the appointment of Ms. Lu Jiandong as the Chief Financial Officer of the Company.
TechnoDerma announced the appointment of key members of the Scientific Advisory Board, Professor Xiang Leihong, a dermatologist at Fudan University School of medicine, Dr. John Mao, a senior drug R & D expert in the San Francisco Bay area, Professor G
TechonoDerma is an innovation-oriented R&D biotech focusing on the development of novel small molecule drugs for dermatological conditions. Located in Jiaxing Xiuzhou Biopharmaceutical National Park, TechnoDerma has been designated as a leading enterprise by the Jiaxing Municipal Government of Zhejiang Province.
The company's current R&D pipeline includes candidate drugs for androgenetic alopecia (AGA), atopic dermatitis (AD), psoriasis, and systemic lupus erythematosus (SLE). TechnoDerma's first and the most advanced research and development program is the first-in-class small molecule drug candidate TDM-105795 for the treatment of AGA, which will finish Phase I clinical trial by end of 2022 and begin Phase II trial in early 2023.